Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

Cited 10 time in scopus
Metadata Downloads
Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates
S H Hong; Hanseul Oh; Y W Park; H W Kwak; E Y Oh; H J Park; K W Kang; Green KimBon-Sang KooEun-Ha HwangSeung Ho Baek; H J Park; Y S Lee; Y J Bang; J Y Kim; S H Bae; S J Lee; K W Seo; H Kim; T Kwon; S M Lee; Jung Joo Hong; J H Nam
Bibliographic Citation
Science Advances, vol. 7, no. 22, pp. eabg7156-eabg7156
Publication Year
Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), various vaccines are being developed, with most vaccine candidates focusing on the viral spike protein. Here, we developed a previously unknown subunit vaccine comprising the receptor binding domain (RBD) of the spike protein fused with the tetanus toxoid epitope P2 (RBD-P2) and tested its efficacy in rodents and nonhuman primates (NHPs). We also investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy. Immunization with N and RBD-P2 (RBDP2/N) + alum increased T cell responses in mice and neutralizing antibody levels in rats compared with those obtained using RBD-P2 + alum. Furthermore, in NHPs, RBD-P2/N + alum induced slightly faster SARS-CoV-2 clearance than that induced by RBD-P2 + alum, albeit without statistical significance. Our study supports further development of RBD-P2 as a vaccine candidate against SARS-CoV-2. Also, it provides insights regarding the use of N in protein-based vaccines against SARS-CoV-2.
Amer Assoc Advancement Science
Appears in Collections:
Ochang Branch Institute > Division of National Bio-Infrastructure > National Primate Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.